ClinicalTrials.gg
RecruitingNCT05927389BONeMOVEUpdated May 8, 2026

Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta

An interventional study of Adapted Physical Activity program in Osteogenesis Imperfecta, sponsored by University Hospital, Toulouse. Recruiting at 2 sites in France. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
7 Years to 18 Years
Sex
All
01

Study summary

This research study aims to evaluate the effect of a 6-month adapted physical activity program (APA) on the endurance capacities (evaluated as the maximum oxygen consumption [VO2 peak]) of children and adolescents with Osteogenesis Imperfecta.

Read the detailed description

Osteogenesis Imperfecta (OI) is a rare genetic disease characterised mainly by bone fragility, decreased bone mass and a susceptibility to fractures of varying severity. Different forms have been described according to the severity of the bone manifestations. Although it is a genetically heterogeneous disease, approximately 90% of OI patients have a mutation in the gene encoding gene encoding type 1 collagen, a major component of the extracellular matrix.

Chronic fatigue and decreased physical endurance are almost constant complaints of patients with OI (more than 95% according to some studies), which impacts the activities of daily living and quality of life of these patients. The causes of this decrease in endurance are multifactorial involving prolonged immobilisation secondary to fractures, chronic osteoarticular pain, but also primary muscle damage.

Mechanography studies carried out in children with OI have shown a significant deficit in muscle function in terms of both strength and power.

In healthy adults, physical inactivity is an important predictor of feeling of tired. In addition, in some chronic diseases (such as multiple sclerosis, rheumatoid arthritis or systemic lupus erythematosus), physical activity and training have been shown to be effective in improving muscle strength and functional capacity as well as fatigue and quality of life. In OI, it has been reported that physical activity improves muscle function and bone mass. Patients with OI should therefore benefit from a regular exercise programme taking into account their risk of fracture.

This study aims to evaluate the effect of a life-skills physical activity (LSPA) programme on the endurance capacities and quality of life of children and adolescents with OI.

The VO2 peak evolution will be evaluated after 6 months of program. This is a recognized parameter for the evaluation of endurance and has been validated in children. The hypothesis of this study is that the implementation of a physical activity program adapted to the daily life and interests of the child with OI will efficiently improve endurance, prevent deconditioning and promote long term benefits.

02

Conditions studied

  • Osteogenesis Imperfecta

Keywords

  • Osteogenesis Imperfecta
  • Children
  • Adolescents
  • Maximum oxygen consumption
  • Adapted physical activity
  • Effort rehabilitation
03

In context

Osteogenesis Imperfecta

84 studies on the registry are indexed under Osteogenesis Imperfecta; 20 are open to participants now.

This study's planned enrollment of 30 is close to the median of 28 across 60 interventional studies indexed under Osteogenesis Imperfecta.

Browse Osteogenesis Imperfecta studies →

Lead sponsor

University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed Osteogenesis Imperfecta
  • Informed and written consent signed by at least one of the two holders of parental authority
  • Patient affiliated to a social security scheme or equivalent

Exclusion criteria

Exclusion Criteria:

  • Non-walking children (unable to perform the effort test)
  • Pregnant or breastfeeding
  • Participation in other interventional research
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental group: 6 months APA program

    The various assessments will be carried out during 2 visits at 6 months interval as part of the usual follow-up at the "Constitutional Bone Diseases" unit at the Toulouse University Hospital. The APA program built from the initial assessment will be returned to the child and his family during a videoconference. In addition, a regular reassessment and adjustment of this program will be made every 15 days during phone calls by the APA coach.

    Other: Adapted Physical Activity program

Interventions

  • OtherAdapted Physical Activity program

    The Adaptated Physical Activity program consists of a Personalized Training Program adapted to each patient's condition and capacities

06

What researchers measure

Primary outcomes

  1. Change from Baseline maximum endurance capacity at 6 months

    Maximum oxygen consumption (VO2 peak) during an exercise test will be measured

    Time frame: Change from Baseline to 6 months

Secondary outcomes

  1. Change from baseline quality of life questionnaire score at 6 months

    Osteogenesis Imperfecta Specific Quality of Life Questionnaire (OIQoL). Total scores are based on a 0-100 scale, where a high score represents better quality of life

    Time frame: Change from Baseline to 6 months

  2. Change from baseline number of steps at 6 months

    6-minute walk test (6MWT) assessed by connected watch

    Time frame: Change from Baseline to 6 months

  3. Change from baseline Weight at 6 months

    Body Mass Index

    Time frame: Change from Baseline to 6 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr;16(2):101-16. doi: 10.1136/jmg.16.2.101. PubMed 458828 ↗
  • Rossi V, Lee B, Marom R. Osteogenesis imperfecta: advancements in genetics and treatment. Curr Opin Pediatr. 2019 Dec;31(6):708-715. doi: 10.1097/MOP.0000000000000813. PubMed 31693577 ↗
  • Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F, Perlini S, Cavarzere P, Antoniazzi F. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010 Sep 7;6:367-81. doi: 10.2147/tcrm.s5932. PubMed 20856683 ↗
  • Arponen H, Waltimo-Siren J, Valta H, Makitie O. Fatigue and disturbances of sleep in patients with osteogenesis imperfecta - a cross-sectional questionnaire study. BMC Musculoskelet Disord. 2018 Jan 8;19(1):3. doi: 10.1186/s12891-017-1922-5. PubMed 29310646 ↗
  • Harsevoort AGJ, Gooijer K, van Dijk FS, van der Grijn DAFM, Franken AAM, Dommisse AMV, Janus GJM. Fatigue in adults with Osteogenesis Imperfecta. BMC Musculoskelet Disord. 2020 Jan 3;21(1):6. doi: 10.1186/s12891-019-3000-7. PubMed 31900144 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05927389
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Feb 26, 2024
Primary completion
Aug 26, 2027 (estimated)
Completion
Aug 26, 2027 (estimated)
Last update
May 8, 2026

Study contacts

Thomas EDOUARD, MD
Contact
edouard.t@chu-toulouse.fr
05 61 77 61 10
Marjolaine WILLEMS, MD
Contact
m-willems@chu-montpellier.fr
Thomas EDOUARD, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion